The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2022 | Updates in immunotherapy and mRNA vaccines in lung cancer
Shobhit Baijal, MBBS, MRCP, MRCP, The University Hospital Birmingham NHS Trust, Birmingham, UK, provides an overview of the topics discussed during the session on translational oncology at the 2022 British Thoracic Oncology Group (BTOG) Conference. Dr Baijal highlights advances in mRNA vaccines targeting lung cancer, which have shown promising results despite being in early clinical trials, as well as checkpoint inhibitors, which have become an integral part of the treatment landscape. Further research is, however required for patients who progress from immunotherapy. This interview took place at the 20th Annual BTOG Conference 2022.
Disclosures
Dr Baijal has received honoraria from: Abbvie, Amgen, AstraZeneca, Boehringer Ingleheim, Bristol Myers-Squibb, Chugai, Daiichi Sankyo, FoundationOne, GlaxoSmithKline, Janssen, Lilly, Merck Serono, Novartis, Pierre Fabre, Pfizer, Roche, Servier, Sanofi and Takeda.
